PP242 Synergizes With Suberoylanilide Hydroxamic Acid to Inhibit Growth of Ovarian Cancer Cells

Yu, Qin; Zhao, Xuejiao; Fang, Yong

doi:10.1097/igc.0000000000000238

Cited by 5 publications

(2 citation statements)

References 21 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the current study demonstrate that the role of PP242 in bladder cancer cells is more important for mTORC2, however further research is required to confirm the exact mechanism. Furthermore, numerous previous studies demonstrated that PP242 inhibited cell proliferation and induced apoptosis by its targeting of TORC2 (26)(27)(28)(29)(30). In order to confirm that PP242 targets mTORC2, the present study also examined the phosphorylation of mTOR.…”

Section: Discussionmentioning

confidence: 70%

PP242 suppresses bladder cancer cell proliferation and migration through deactivating the mammalian target of rapamycin complex 2/AKT1 signaling pathway

Zhang

Kong

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

While most cancer types are resistant to mammalian target of rapamycin complex 1 (mTORC1) inhibitor rapamycin, recent studies have identified mTORC2 as an important prospective therapeutic target for cancer. The present study assessed the effects of mTORC2 inhibitor PP242 on the proliferation and migration of bladder cancer cells by using Cell Counting Kit‑8, 5‑ethynyl‑2'‑deoxyuridine incorporation, wound healing and Transwell assays. Furthermore, the phosphorylation status of downstream signaling proteins of mTORC1 and mTORC2 was assessed using western blot analysis. The results demonstrated that PP242 concentration‑dependently inhibited the proliferation of bladder cancer cells. Simultaneously, the migration ability of bladder cancer cells was suppressed by PP242. In addition, PP242 markedly restrained the phosphorylation of AKT1 and mTORC2, while the phosphorylation status of S6K1 and mTORC1 was not affected. These results suggested that PP242 exerts potent inhibitory effects on bladder cancer cells by modulating the activity of the mTORC2/AKT1 pathway.

show abstract

Section: Discussionmentioning

confidence: 70%

PP242 suppresses bladder cancer cell proliferation and migration through deactivating the mammalian target of rapamycin complex 2/AKT1 signaling pathway

Zhang

Kong

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…MORAB-003 (farletuzumab), which is a humanized anti-folate receptor alpha (FRα) monoclonal antibody derived from optimization of the LK26 molecule, contributed to human ovarian cancer cells (A2780, HeyA8, SKOV3ip1 and IGROV1) death associated with increased expression of LC3-II and enriched autophagic vacuolization in ovarian cancer [74]. Furthermore, cotreatment of suberoylanilide hydroxamic acid (SAHA) and PP242 inhibited growth of ovarian cancer cells (SKOV3 and A2780) synergistically by promoting LC3-II expression and decreasing p62 expression [77]. Likewise, combination treatment of a PARP inhibitor and a selective EGFR inhibitor erlotinib in ovarian cancer A2780 xenografts had an apparently enhanced antitumor effect via enhancing autophagy compared to their monotherapy [78].…”

Section: Autophagy and Ovarian Carcinomamentioning

confidence: 99%

Autophagy as an emerging therapy target for ovarian carcinoma

et al. 2016

View full text Add to dashboard Cite

Autophagy is a conserved cellular self-digestion pathway for maintenance of homeostasis under basal and stressed conditions. Autophagy plays pivotal roles in the pathogenesis of many diseases, such as aging-related diseases, autoimmune diseases, cardiovascular diseases, and cancers. Of special note is that accumulating data suggest an intimate relationship between autophagy and ovarian carcinoma. Autophagy is well identified to act as either as a tumor-suppressor or as a tumor-promoter in ovarian carcinoma. The exact function of autophagy in ovarian carcinoma is highly dependent on the circumstances of cancer including hypoxic, nutrient-deficient, chemotherapy and so on. However, the mechanism underlying autophagy associated with ovarian carcinoma remains elusive, the precise role of autophagy in ovarian carcinoma also remains undetermined. In this review, we tried to sum up and discuss recent research achievements of autophagy in ovarian cancer. Moreover, waves of novel therapies ways for ovarian carcinoma based on the functions of autophagy were collected.

show abstract

Immobilization of transition-metal hydroxamates on polystyrene resins: Effective biomimetic heterogeneous catalysts for aerobic oxidation of ethylbenzene

Wang

et al. 2015

Chem. Res. Chin. Univ.

View full text Add to dashboard Cite

PP242 Synergizes With Suberoylanilide Hydroxamic Acid to Inhibit Growth of Ovarian Cancer Cells

Abstract: These results suggest that the combination of SAHA and PP242 may lead to a novel strategy in treating patients with ovarian cancer.

Cited by 5 publications

References 21 publications

PP242 suppresses bladder cancer cell proliferation and migration through deactivating the mammalian target of rapamycin complex 2/AKT1 signaling pathway

PP242 suppresses bladder cancer cell proliferation and migration through deactivating the mammalian target of rapamycin complex 2/AKT1 signaling pathway

Autophagy as an emerging therapy target for ovarian carcinoma

Immobilization of transition-metal hydroxamates on polystyrene resins: Effective biomimetic heterogeneous catalysts for aerobic oxidation of ethylbenzene

Contact Info

Product

Resources

About